InflaRx N.V. (IFRX) – What Are Researchers Thinking About This Stock?

Shares of InflaRx N.V. (NASDAQ:IFRX) have been given an average recommendation of “Moderate Buy” by the nine research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $7.43.

Several brokerages have issued reports on IFRX. Zacks Research lowered shares of InflaRx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 25th. Needham & Company LLC initiated coverage on InflaRx in a research report on Monday, September 14th. They set a “buy” rating and a $8.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research note on Monday, September 21st. Finally, Cantor Fitzgerald upped their price target on shares of InflaRx from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th.

InflaRx Stock Down 2.5%

Shares of IFRX stock opened at $1.18 on Friday. InflaRx has a 12-month low of $0.80 and a 12-month high of $2.95. The firm has a fifty day moving average of $1.74 and a 200-day moving average of $1.64. The company has a market capitalization of $173.90 million, a price-to-earnings ratio of -3.03 and a beta of 2.38.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.04. On average, equities analysts expect that InflaRx will post -0.22 EPS for the current year.

Institutional Investors Weigh In On InflaRx

A number of large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. grew its stake in InflaRx by 47.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 23,600 shares of the company’s stock valued at $44,000 after buying an additional 7,600 shares during the last quarter. T3 Companies LLC boosted its stake in InflaRx by 32.9% in the 3rd quarter. T3 Companies LLC now owns 440,000 shares of the company’s stock valued at $792,000 after purchasing an additional 108,986 shares during the period. SteelPeak Wealth LLC bought a new stake in InflaRx in the 3rd quarter valued at $419,000. AXQ Capital LP acquired a new position in InflaRx in the 2nd quarter valued at $41,000. Finally, Montanova Capital LLC increased its position in InflaRx by 189.1% during the 2nd quarter. Montanova Capital LLC now owns 22,933,910 shares of the company’s stock worth $51,372,000 after buying an additional 15,000,000 shares during the period. Institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. is a biotechnology company that develops therapies for inflammatory and autoimmune diseases. Its research focuses on the complement system, a part of the immune system that can contribute to inflammation and tissue damage. The company’s lead antibody, vilobelimab, targets the complement protein C5a. In 2023, the U.S. Food and Drug Administration granted emergency use authorization for vilobelimab, marketed as Gohibic, for certain hospitalized adults with COVID-19. InflaRx is also investigating the drug in other inflammatory conditions.